HeartFlow Inc's stock surged 9.72% during intraday trading on Wednesday, following a significant company announcement.
The sharp rise appears to be driven by the company's update on its NAVIGATE-PCI Registry clinical study. HeartFlow announced new developments in its data pathway for AI-guided stent planning, which investors likely viewed as a positive advancement for the company's medical technology platform.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.